Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13775212 | 1.00 | KDM1A (0.32) | KDM1ACYP1A2S1PR1CYP2A6TSHR | |
| SCHEMBL2544680 | 0.97 | CYP1A2 (0.33) | KDM1ACYP1A2S1PR1CYP2A6TSHR | |
| SCHEMBL13775204 | 0.94 | KDM1A (0.31) | KDM1ACYP1A2 | |
| SCHEMBL13775210 | 0.92 | — | — | |
| SCHEMBL13775214 | 0.92 | KDM1A (0.32) | KDM1A | |
| SCHEMBL1376567 | 0.91 | CYP1A2 (0.38) | KDM1ACYP1A2S1PR1CYP2A6TSHR | |
| SCHEMBL20115617 | 0.89 | CYP1A2 (0.39) | KDM1ACYP1A2S1PR1CYP2A6 | |
| SCHEMBL2536348 | 0.89 | CYP1A2 (0.34) | CYP1A2CYP2A6TSHR | |
| SCHEMBL13775216 | 0.87 | KDM1A (0.34) | KDM1A | |
| SCHEMBL18978244 | 0.86 | S1PR1 (0.36) | KDM1ACYP1A2S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090189522-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDERNITSU KOSAN CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-20090189522-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDERNITSU KOSAN CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| US-7524568-B2 | Aromatic amine derivative and organic electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-7524568-B2 | Aromatic amine derivative and organic electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2009-04-28 | — | — | US | disclosed |
| US-20080268283-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2008-10-30 | — | — | US | disclosed |
| US-20080268283-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | IDEMITSU KOSAN CO., LTD. (JP) | 2008-10-30 | — | — | US | disclosed |
| US-7425653-B2 | Aromatic amine derivative and organic electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
| US-7425653-B2 | Aromatic amine derivative and organic electroluminescence device employing the same | IDEMITSU KOSAN CO., LTD. (JP) | 2008-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080268283-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | TYR, MAOA, AOC2 | KDM1A 159/4885CYP1A2 345/4885S1PR1 4540/4885 |
| US-20090189522-A1 | AROMATIC AMINE DERIVATIVE AND ORGANIC ELECTROLUMINESCENCE DEVICE EMPLOYING THE SAME | TYR, MAOA, AOC2 | KDM1A 159/4885CYP1A2 345/4885S1PR1 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.